Physician profile
Haley Wiggins
NPI 1851154744
$837.29
in general payments reported to CMS, 2019-2025
19 companies · $666 in 2025
The $666 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $171 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $98.88 | 2024-2025 | Evenity, Prolia, Repatha |
| Sequel Med Tech, LLC | $72.56 | 2025 | Twiist |
| Novo Nordisk INC | $71.75 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $68.32 | 2025 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $58.71 | 2025 | Zepbound, Mounjaro, Jardiance |
| Tandem Diabetes Care, INC. | $56.80 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $47.05 | 2024-2025 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $44.44 | 2025 | Farxiga |
| Almatica Pharma LLC | $43.88 | 2025 | Teriparatide |
| Bayer Healthcare Pharmaceuticals INC. | $42.58 | 2025 | |
| Radius Health, INC. | $40.50 | 2025 | Tymlos |
| Insulet Corporation | $36.46 | 2024 | Omnipod |
| Averitas Pharma INC. | $28.58 | 2025 | Qutenza |
| Ascensia Diabetes Care US INC. | $27.57 | 2024 | |
| Sandoz INC. | $22.34 | 2025 | Hyrimoz |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $20.75 | 2024 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $20.60 | 2024 | Ilet Bionic Pancreas |
| Madrigal Pharmaceuticals | $19.25 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $16.27 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.